Real-world evidence from its humanitarian use in Ukraine to treat wartime injuries further bolstered the company’s biologics license application.
Humacyte's SYMVESS receives FDA approval as a bioengineered vascular conduit with promising clinical outcomes for arterial injury repair.Quiver AI SummaryHumacyte, Inc. has announced that the FDA has granted...
Humacyte (HUMA) faces mounting investor scrutiny as a class action lawsuit alleges the company failed to disclose critical manufacturing deficiencies at its Durham, North Carolina facility. These issues,...
Humacyte's (HUMA) innovative Acellular Tissue Engineered Vessel (ATEV) technology remains promising, but the FDA’s delay in approving its lead product for vascular trauma has placed the company in a...
Humacyte (HUMA) faces mounting legal challenges as a class action lawsuit has been filed against the company for alleged violations of federal securities laws. The lawsuit, filed on behalf of investors...
Humacyte, Inc. CEO Laura Niklason will present at the Piper Sandler Healthcare Conference on December 5, 2024, in New York.Quiver AI SummaryHumacyte, Inc. has announced that its Founder, President, and...
Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon Binder, collectively...